Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Revenue (2019 - 2025)

Historic Revenue for Keros Therapeutics (KROS) over the last 6 years, with Q3 2025 value amounting to $14.3 million.

  • Keros Therapeutics' Revenue rose 357577.32% to $14.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $246.7 million, marking a year-over-year increase of 3779831.03%. This contributed to the annual value of $3.6 million for FY2024, which is 225099.34% up from last year.
  • Per Keros Therapeutics' latest filing, its Revenue stood at $14.3 million for Q3 2025, which was up 357577.32% from $18.2 million recorded in Q2 2025.
  • In the past 5 years, Keros Therapeutics' Revenue ranged from a high of $211.2 million in Q1 2025 and a low of -$1000.0 during Q1 2021
  • For the 5-year period, Keros Therapeutics' Revenue averaged around $21.8 million, with its median value being $388000.0 (2024).
  • As far as peak fluctuations go, Keros Therapeutics' Revenue skyrocketed by 180010000.0% in 2022, and later soared by 202727.27% in 2024.
  • Quarter analysis of 5 years shows Keros Therapeutics' Revenue stood at $17.9 million in 2021, then increased by 0.56% to $18.0 million in 2022, then crashed by 99.21% to $143000.0 in 2023, then surged by 2027.27% to $3.0 million in 2024, then skyrocketed by 368.84% to $14.3 million in 2025.
  • Its last three reported values are $14.3 million in Q3 2025, $18.2 million for Q2 2025, and $211.2 million during Q1 2025.